panel-4-post-grant-proceedings-in-life-sciences

29 May 2026VideosRegulation & IndustryPhil Hirschhorn, Panitch Law | Erin Dunston, Panitch Schwarze | Mythili Markowski, Regeneron | Victoria Pedanou, Sanofi

WATCH: Post-grant proceedings in life sciences—strategic offense and defense in the US and Europe

Phil Hirschhorn, Partner at Panitch Law, moderates a discussion with Erin Dunston, Partner at Panitch Schwarze; Mythili Markowski, Patent Attorney at Regeneron; and Victoria Pedanou, Patent Counsel at Sanofi.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Regulation & Industry

Inside the deal boom: LSIPR’s five-part M&A series—all in one place

17 September 2026 Featuring interviews with dozens of lawyers, LSIPR published a five-part deep dive into the levers driving a surge in life sciences dealmaking. Author Marisa Woutersen discovered where buyers are placing their bets, what sellers can do to make themselves 'acquisition-ready', and why IP can make or break a deal.

Regulation & Industry

Perfect Pitch: Inside the scheme that gets junior lawyers selling to clients

14 September 2026 Pitching for business has always been a partner’s game. One in-house team decided junior lawyers needed a seat at the table, building a programme to close an “industry-wide gap” in vital experience. Marisa Woutersen spoke with organisers Regeneron and associates from A&O Shearman, Hoyng Rokh Monegier, and Bristows, who stepped up to ‘sell’ their firms.

Regulation & Industry

Built to be bought? What makes companies acquisition-ready

11 September 2026 For biotech companies, promising science is no longer enough to attract a pharma buyer. Lawyers from Morrison Foerster, Polsinelli, Morgan Lewis and Dechert explain what makes an acquisition target truly deal-ready. Marisa Woutersen explores what companies should get right before a potential acquirer comes knocking.

More features

Leading European patent litigator to join Carpmaels & Ransford

CIPA Congress: Sustainability is essential for the profession and the planet

Non-profit sues Cambrex over anticancer drug manufacturing trade secrets

Inside the deal boom: LSIPR’s five-part M&A series—all in one place

Amgen hit with lawsuit over its proposed Opdivo biosimilar

Beyond the primary patent: How pharma can build competitive barriers

Australian biotech sues Grail over multi-cancer blood test

K&L Gates hires six-strong team of IP and corporate lawyers from Pillsbury

WATCH: Post-grant proceedings in life sciences—strategic offense and defense in the US and Europe

More on this story

Editor's picks

Editor's picks

More features